NCT00171704 - A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | Biotech Hunter

Enrollment

263

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

Interventions

DRUG

Letrozole

2.5 mg tablets and supplied in bottles with 6-monthly supplies.

DRUG

Tamoxifen

20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)

Trial Locations (13)

Unknown

Novartis Investigative Site, Aalborg

Novartis Investigative Site, Aarhus

Novartis Investigative Site, Copenhagen

Novartis Investigative Site, Esbjerg

Novartis Investigative Site, Herlev

Novartis Investigative Site, Herning

Novartis Investigative Site, Hillerød

Novartis Investigative Site, Kløvervænget

Novartis Investigative Site, Roskilde

Novartis Investigative Site, Sønderborg

Novartis Investigative Site, Vejle

Novartis Investigative Site, Viborg

Novartis Investigative Site, Sheffield